13G Filing: Opaleye Management and Tonix Pharmaceuticals Holding Corp. (TNXP)

Page 5 of 8

Page 5 of 8 – SEC Filing

Item 1(a).		Name of Issuer:

		The name of the issuer is Tonix Pharmaceuticals Holding Corp. (the “Company”).

Item 1(b).		Address of Issuer’s Principal Executive Offices:

		The Company’s principal executive offices are located at 509 Madison Av, Suite 306, New York, NY 10022.

Item 2(a).		Name of Person Filing.

		This statement is filed by the entities and persons listed below, who are collectively referred to herein as “Reporting Persons” with respect to the shares of common stock of the Company:

		Opaleye Fund

		Opaleye LP (the “Opaleye Fund”), a private fund formed in the state of Delaware.

		Investment Manager

		Opaleye Management Inc. (the “Investment Manager”), with respect to the shares of common stock held by the Opaleye Fund, a private fund to which the Investment Manager serves as investment manager.

		Reporting Individual

		Mr. James Silverman (the “Reporting Individual”), with respect to the shares of common stock held by the Opaleye Fund. Mr. Silverman is the President of the Investment Manager.

Item 2(b).		Address of Principal Business Office or, if None, Residence.

		One Boston Place, 26^th Floor
		Boston, Massachusetts 02108

Item 2(c).		Citizenship.

		Citizenship is set forth in Row 4 of the cover page for each Reporting Person and is incorporated herein by reference for each such Reporting Person.

Item 2(d).		Title of Class of Securities.

		Common Stock, $0.001 par value

Item 2(e).		CUSIP Number.

		890260409

Item
3. Type of Person

Not
applicable.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 5 of 8